Drug

D0270 | Valinomycin

Molecular Formula C54H90N6O18
Molecular Weight 1111.3
Structure
State solid
Description potassium ionophores; dodecadepsipeptide; transport of potassium; antibiotic; K+-selective ionophoric cyclodepsipeptide;

Toxicity Dose Time Species Model Method Action Positive criterion Reference
TRANSPORT OF CHARGE BUT NOT PROTONS affect 201
GLUCOSE GALACTOSE IC50 RATIO 1 LUHMES (Lund human mesencephalic) cells Glc–Gal–NeuriTox assay Negative EC25(NA) [Glc/Gal] 326
MITOCHONDRIAL MOTILITY 10 μM decrease 217

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 44 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]


H310 (100%): Fatal in contact with skin [Danger Acute toxicity, dermal]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


P262, P264, P270, P280, P301+P310, P302+P350, P310, P321, P322, P330, P361, P363, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
rabbit LD50 skin 5mg/kg (5mg/kg) Drug and Chemical Toxicology. Vol. 8, Pg. 451, 1985.
rat LD50 intraperitoneal 800ug/kg (0.8mg/kg) Drug and Chemical Toxicology. Vol. 8, Pg. 451, 1985.
mouse LD50 subcutaneous 4140ug/kg (4.14mg/kg) Antibiotics and Chemotherapy Vol. 12, Pg. 482, 1962.
mouse LD50 oral 2500ug/kg (2.5mg/kg) "Antibiotics: Origin, Nature, and Properties," Korzyoski, T., et al., eds., Washington, DC, American Soc. for Microbiology, 1978Vol. 1, Pg. 325, 1978.
mouse LD50 intraperitoneal 390ug/kg (0.39mg/kg) National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse LD50 intravenous 180ug/kg (0.18mg/kg) Cancer Research. Vol. 46, Pg. 5518, 1986.
rat LD50 oral 4mg/kg (4mg/kg) Drug and Chemical Toxicology. Vol. 8, Pg. 451, 1985.


  • (3R,6R,9S,12S,15R,18R,21S,24S,27R,30R,33S,36S)-3,6,9,15,18,21,27,30,33-nonaisopropyl-12,24,36-trimethyl-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexaazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone (3R,6R,9S,12S,15R,18R,21S,24S,27R,30R,33S,36S)-3,6,9,15,18,21,27,30,33-nonaisopropyl-12,24,36-trimethyl-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone 1,7,13,19,25,31-Hexaoxa-4,10,16,22,28,34-hexaazacyclohexatriacontane- 2,5,8,11,14,17,20,23,26,29,32,35-dodecone, 12,24,36-trimetyl-3,6,9,15,18,21,27,30,33-nonakis(1-methylethyl)-
    2001-95-8 4-27-00-09728 (Beilstein Handbook Reference) AKOS024457589
    Antibiotic N-329 B BDBM50237619 BRN 0078657
    CCG-208283 CHEBI:28545 CHEMBL223643
    CS-0029275 Cyclic(D-.alpha.-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-.alpha.-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-.alpha.-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl ) Cyclic(D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl)
    Cyclo(D-?-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-?-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-?-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl) EINECS 217-896-6 HSDB 6423
    HY-N6693 N561YS75MN NSC 122023
    NSC122023 Potassium ionophore I Potassium ionophore I - cocktail B, Selectophore(TM)
    Q417504 SR-05000002323 SR-05000002323-2
    UNII-N561YS75MN Valinomicin balinomycin
    cyclo[-D-O-Val-D-Val-L-O-Ala-L-Val]3 valino valinomycin

    DrugBank Name Valinomycin
    DrugBank DB14057
    CAS Number 2001-95-8
    PubChem Compound 3000706
    KEGG Compound ID C06684
    ChEBI 28545
    PharmGKB PA151917011
    ChemSpider 21493802
    BindingDB 50237619.0
    Wikipedia Valinomycin